Back to Interventions
Substance / Medication

Alfuzosin

SNOMED 395954002UMLS C0051150

Overview

Active Ingredient
alfuzosin
RxNorm CUI
17300

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Benign prostatic hyperplasia
Hyperplasia of prostate

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Prostate specific Ag

LOINC 10508-0

secondary

Clinical Trials

10 trials linked to this intervention

10
Total Trials
0
Recruiting
1
With Results

Recent Trials

Evaluation of Symptom-specific Goal Achievement

NCT00836823Phase 4Completed130 enrolled

The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients

NCT00696761Phase 4Completed232 enrolled

The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil

NCT03144596Phase 4Completed63 enrolled

ALF-ONE : ALFuzosin ONcE Daily

NCT00280605Phase 4Completed200 enrolled

SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

NCT00486785Phase 4Completed431 enrolled
View all 10 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.
Liu Chenli, Zeng Guohua, Kang Ran et al. · PLoS One · 2015
PMID: 26244843Meta-AnalysisFull text (PMC)
The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo.
Kwon Jong Kyou, Cho Kang Su, Oh Cheol Kyu et al. · BMC Urol · 2015
PMID: 26104313Meta-AnalysisFull text (PMC)
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
MacDonald Roderick, Wilt Timothy J · Urology · 2005
PMID: 16230138Meta-Analysis
Effects of Alfuzosin, an α-Adrenergic Antagonist, on Anal Pressures and Bowel Habits in Women With and Without Defecatory Disorders.
Chakraborty Subhankar, Feuerhak Kelly, Muthyala Anjani et al. · Clin Gastroenterol Hepatol · 2019
PMID: 30130627RCTFull text (PMC)
Effects of psychosensory stimulation on anal pressures: Effects of alfuzosin.
Muthyala Anjani, Feuerhak Kelly J, Harmsen William S et al. · Neurogastroenterol Motil · 2019
PMID: 31032543RCTFull text (PMC)
Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.
Liu Shucheng, Yu Ying, Gao Yang et al. · Urolithiasis · 2016
PMID: 26242466RCT
The effects of tamsulosin and alfuzosin on iris morphology: an ultrasound biomicroscopic comparison.
Aktas Zeynep, Yuksel Nilay, Ceylan Gurhan et al. · Cutan Ocul Toxicol · 2015
PMID: 24730669RCT
Alfuzosin treatment improves the rate and time for stone expulsion in patients with distal uretral stones: a prospective randomized controlled study.
El Said Nouran O, El Wakeel Lamia, Kamal Khaled M et al. · Pharmacotherapy · 2015
PMID: 26011140RCT
Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Öztürk M İ, Kalkan S, Koca O et al. · Andrologia · 2012
PMID: 22211956RCT
Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial.
Chau Lysander Hin, Tai Dominic Chi Kin, Fung Berry Tat Chow et al. · Int J Urol · 2011
PMID: 21592234RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X
Urology Physician

Urology

NUCC 208800000X
Find a Provider

Health Goals

Goals connected through associated conditions

Support Prostate Health

Quick Facts

Type
Substance / Medication
Fully Specified Name
Alfuzosin (substance)
SNOMED CT
395954002
UMLS CUI
C0051150
RxNorm CUI
17300

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

2
Conditions
1
Biomarkers
2
Specialists
0
Symptoms
10
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.